Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02826694 · ClinicalTrials.gov registry record · NA

North Carolina Newborn Exome Sequencing for Universal Screening

A NA study of Hearing Loss and Metabolism, Inborn Errors, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
NA
Development phase
106
Enrollment target
1
Study location

NCT02826694 is a NA study of Hearing Loss and Metabolism, Inborn Errors that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 106 participants, below the 6,119-participant average among 58 other Hearing Loss trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02826694, a NA study of Hearing Loss and Metabolism, Inborn Errors, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
NA
Development phase
106 participants
Enrollment target
1
Study location

Study Summary

The NC NEXUS research study is exploring the utility of next generation sequencing in newborn screening and parental decision making. The National Institutes of Health (NICHD and NHGRI) are co-funding this study under a single U-19.

Interventions

  • GENETIC Well infant, whole exome sequencing
  • GENETIC Diagnosed, whole exome sequencing

Study Locations (1)

North Carolina

  • UNC Hospitals - Chapel Hill

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2016-06
Est. Completion 2019-06-30
Phase NA

What the Registry Record Tells You About NCT02826694

The ClinicalTrials.gov registry entry for NCT02826694 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,119-participant average among 58 other Hearing Loss trials with a reported enrollment target (98% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Hearing Loss appearing as the primary indexed condition, and to 2 interventions - of which Well infant, whole exome sequencing is the first listed.

NCT02826694 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT02826694 about?

NCT02826694 is a clinical study titled "North Carolina Newborn Exome Sequencing for Universal Screening". The NC NEXUS research study is exploring the utility of next generation sequencing in newborn screening and parental decision making. The National Institutes of Health (NICHD and NHGRI) are co-funding this study under a single U-19.

What is the current status of trial NCT02826694?

This trial is currently completed. It is a NA study. The enrollment target is 106 participants. The study started on 2016-06. Estimated completion is 2019-06-30.

What conditions does trial NCT02826694 study?

This clinical trial studies the following conditions: Hearing Loss, Metabolism, Inborn Errors, Hereditary Disease.

What interventions are being tested in trial NCT02826694?

The interventions under investigation include: Well infant, whole exome sequencing (GENETIC), Diagnosed, whole exome sequencing (GENETIC).

Who is sponsoring clinical trial NCT02826694?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02826694 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hearing Loss

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.